What To Know
- TeraRecon will accelerate the use of AI in other clinical specialties, including neurology and oncology, in addition to its market-leading solutions in radiology, cardiology, and vascular surgery.
- We believe that TeraRecon AI technology can continue to deliver unprecedented benefits to doctors and patients and expand into new areas of the healthcare enterprise.
Using newly patented AI and platform technology, SymphonyAI Group reports TeraRecon will continue to focus on expanding its open platform for advanced visualization and AI-driven solutions. TeraRecon will accelerate the use of AI in other clinical specialties, including neurology and oncology, in addition to its market-leading solutions in radiology, cardiology, and vascular surgery. The news was announced today (March 4, 2020).
SymphonyAI Group will invest in infrastructure and key initiatives to rapidly produce new advancements and offerings through TeraRecon’s industry-leading engineering and product teams. TeraRecon will operate as an independent portfolio company in the SymphonyAI Group. Synergies with TeraRecon technologies will complement the precision oncology offerings of portfolio company Concerto HealthAI.
Used by over 900 health systems globally, TeraRecon solutions provide radiologists and other highly specialized physicians with the software tools they need to quickly visualize and extract critical clinical data from medical images.
Jeff Sorenson, president and CEO of TeraRecon, said, “In just a few years, our company has not only transformed the realm of advanced visualization with artificial intelligence but also our entire industry. Now with the backing of SymphonyAI Group and the recent recognition of two powerful patents, TeraRecon can think bigger and work faster than ever before. Having been chosen for such an impressive and selective portfolio is truly an honor, and an ideal outcome for our employees, customers, and stockholders.”
Dr. Romesh Wadhwani, founder and CEO of SymphonyAI Group, said, “The SymphonyAI Group mission is to use AI to transform the enterprise. We accelerate high-value AI solutions to market to meet the needs of specific vertical industry use cases. TeraRecon has demonstrated the value AI can play in the medical imaging market. We believe that TeraRecon AI technology can continue to deliver unprecedented benefits to doctors and patients and expand into new areas of the healthcare enterprise.”
Vibhor Rastogi, investment partner at SymphonyAI Group, said, “Artificial intelligence in medical imaging is expected to deliver several breakthroughs spanning a wide range of clinical areas and modalities. With the acquisition of TeraRecon, SymphonyAI Group is bolstering its portfolio of AI-enabled enterprise solutions for the healthcare and life sciences industries. We are committed to leveraging AI to deliver breakthrough therapies and care delivery models.”
TeraRecon CEO Jeff Sorenson will be joined on the company’s board of directors by SymphonyAI Group CEO Romesh Wadhwani and partners Vibhor Rastogi, Leif Pedersen, and Pradyut Shah.
TeraRecon will demonstrate its full suite of AI-driven technologies at the upcoming Health Information and Management Systems Society (HIMSS) 2020 Annual Meeting on March 9-13 in Orlando, Fla. and the European Congress of Radiology (ECR) 2020 Annual Meeting on July 15-19 in Vienna.
Cantor Fitzgerald & Co. acted as exclusive financial advisor to TeraRecon in connection with the transaction.